REVIEW

Recent advances in understanding Epstein-Barr virus [version 1; peer review: 4 approved]

Brent A. Stanfield , Micah A. Luftig

Department of Molecular Genetics and Microbiology, Duke Center for Virology, Duke University Medical Center, Durham, NC, USA

V1 First published: 29 Mar 2017, 6(F1000 Faculty Rev):386
<https://doi.org/10.12688/f1000research.10591.1>

Latest published: 29 Mar 2017, 6(F1000 Faculty Rev):386
<https://doi.org/10.12688/f1000research.10591.1>

Abstract

Epstein-Barr virus (EBV) is a common human herpes virus known to infect the majority of the world population. Infection with EBV is often asymptomatic but can manifest in a range of pathologies from infectious mononucleosis to severe cancers of epithelial and lymphocytic origin. Indeed, in the past decade, EBV has been linked to nearly 10% of all gastric cancers. Furthermore, recent advances in high-throughput next-generation sequencing and the development of humanized mice, which effectively model EBV pathogenesis, have led to a wealth of knowledge pertaining to strain variation and host-pathogen interaction. This review highlights some recent advances in our understanding of EBV biology, focusing on new findings on the early events of infection, the role EBV plays in gastric cancer, new strain variation, and humanized mouse models of EBV infection.

Keywords

EBV, Herpesvirus, Herpes simplex virus, gastric cancer

Open Peer Review

Approval Status

	1	2	3	4
version 1 29 Mar 2017				

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Christian Münz**, Institute of Experimental Immunology, University of Zürich, Zurich, Switzerland
2. **Alan K Chiang**, Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong
3. **Richard M. Longnecker**, Northwestern University, Chicago, Chicago, USA
4. **Bo Zhao**, Brigham and Women's Hospital, Harvard Medical School, Boston, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Micah A. Luftig (micah.luftig@duke.edu)

Competing interests: The authors declare that they have no competing interests.

Grant information: This work received funding support from the National Cancer Institute (grant R01CA140337) and the National Institute of Dental and Craniofacial Research (grant R01DE025994).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Stanfield BA and Luftig MA. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Stanfield BA and Luftig MA. **Recent advances in understanding Epstein-Barr virus [version 1; peer review: 4 approved]** F1000Research 2017, 6(F1000 Faculty Rev):386 <https://doi.org/10.12688/f1000research.10591.1>

First published: 29 Mar 2017, 6(F1000 Faculty Rev):386 <https://doi.org/10.12688/f1000research.10591.1>

Introduction

Epstein-Barr virus (EBV), also known as human herpes virus 4, is a gamma-herpes virus that infects the majority of the world's population. Initial infection with EBV is often asymptomatic but can also manifest as infectious mononucleosis. Following acute lytic replication in epithelial cells, EBV infects B cells where a distinct set of latency-associated genes and transcripts are expressed¹. EBV was first identified in 1964 from cultured tumor cells derived from a patient with Burkitt's lymphoma (BL)². Early studies have demonstrated EBV's ability to transform resting human B cells into lymphoblastoid cell lines (LCLs), further supporting the oncogenic potential of this virus^{3,4}. Since then, EBV infection has been associated with a number of different malignancies of both lymphoid and epithelial origin and accounts for 1.8% of all cancer-related deaths worldwide⁵.

In vivo, EBV infection begins in the oral mucosa. Replication in epithelial cells is typically lytic; however, latent infection of epithelial cells can result in nasopharyngeal carcinoma or gastric cancer (as discussed in more detail later). After replication in the epithelia, virus is primed for entry into B cells, where a transient growth program is thought to mimic a germinal center reaction, ultimately promoting maturation of the infected cell into the peripheral memory B-cell compartment. Advances in next-generation sequencing and the development of humanized mice have led to better ways to identify and understand the natural strain variation that occurs with EBV. New strain variations, particularly with mutations in latency-associated genes, have been identified in various malignancies. Harnessing these new humanized mice enables studies modeling latent infection and pathogenesis of host-restricted pathogens like HIV and EBV. This review will focus on the recent advances in EBV biology and primarily on understanding events in early B-cell infection, the role of EBV in gastric cancer, the breadth of EBV strain variation revealed by next-generation sequencing, and recent discoveries made using humanized mice.

Early events

Initial events of infection

EBV entry into epithelial cells occurs by direct fusion of the viral envelope with the cell plasma membrane; however, entry into B cells requires the virus to be endocytosed before membrane fusion to escape the endosome^{6,7}. B-cell entry requires five viral glycoproteins: gp350/220 allows for attachment by binding to CD21, gp42 binds to major histocompatibility complex (MHC) class II to initiate entry⁸, and the core herpes-virus fusion machinery consisting of gB and the heterodimer gH/gL (Figure 1)¹. Interaction of gp350/220 with the cell surface molecule CD21 results in the alteration of major signaling pathways believed to prime the cell to stable latent EBV infection. In particular, specific transcriptional profiles are involved in the evasion of apoptosis and there is evidence that EBV/CD21 binding alters the expression of specific histone transcripts from clusters 1 and 2 (H2AFC, H2AFM, H2BF, H2BFG, H2BI, H3FA, H3FB, H3FL, H4FL, H4FK, H4FI, H4FK, H4F2, H1F3, and H1F4) (Figure 1)⁹.

Upon entry into B cells, the virion is endocytosed and is released into the cytoplasm following fusion of the virion membrane with endosomal membrane. This process releases the viral tegument proteins into the host cell. One such tegument protein, BNRF1, binds the cellular protein Daxx and disrupts the Daxx-ATRAX complex¹⁰. This complex is known to suppress transcription through histone methylation¹¹. Upon deposition into the nucleus, the viral DNA is associated with cellular histones¹². Daxx-ATRAX might normally support methylation of this new EBV chromatin to suppress transcription of viral genes. However, BNRF1 disruption of the Daxx-ATRAX complex allows early viral latent gene expression (Figure 1)¹⁰.

Packaged, virally encoded RNA is also released upon fusion of the virion membrane with endosomal membrane. In particular, BZLF1 transcripts have been shown to be packaged into viral particles and are translated immediately upon release into the infected cell. These immediately translated proteins then function to transactivate viral promoters initiating the pre-latent phase of EBV infection. EBV also counters T-cell responses through the delivery of BNLF2a mRNA and non-coding EBV-encoded RNA transcripts that induce cellular cytokine synthesis¹³. EBV is known to encode at least 44 microRNAs (miRNAs). Though many of the miRNAs have no known function, it has recently been shown that these virally encoded miRNAs function in immune evasion by specifically suppressing the release of interleukin-12 (IL-12), disrupting CD4⁺ T-cell differentiation into type 1 T helper (Th1) cells, and reducing antigen presentation to CD4⁺ and CD8⁺ T cells. These miRNAs function by interfering with peptide processing, by directly targeting the TAP2 subunit, and by disrupting antigen presentation on MHC-II and MHC-I molecules^{14,15}.

Pre-latent gene expression

Pre-latent gene expression occurs immediately upon deposition of the viral genome into the nucleus of newly infected B cells. Promiscuous expression of both lytic and latent genes occurs at this time with the majority of infected B cells initially expressing EBV immediate-early genes¹⁶. Others have shown that BZLF1, the major transcriptional activator of lytic gene expression, is expressed as early as 1.5 hours post infection in the absence of protein expression, implicating BZLF1 as an immediate-early gene being expressed immediately following B-cell infection¹⁷. This initial burst of lytic gene expression could be essential to the production of progeny virus competent for infecting new B cells¹⁸, or immediate expression of lytic genes could be essential for the survival of latently infected B cells through inactivation of p53¹⁹. However, it is important to note that during this pre-latent phase, genes essential for DNA replication and structural proteins of the virion are not readily detectable¹⁶.

EBV encodes two bcl-2 proteins: BHRF1 and BALF1. Viral mutants lacking both bcl-2 proteins are unable to initiate proliferation and die from immediate apoptosis. Peak expression of these transcripts is detected at 24 hours post infection, implicating BHRF1 and BALF1 in the initial events prior to cell proliferation²⁰. Also, it has recently been shown that BHRF1 is constitutively expressed

Figure 1. Initial events of Epstein-Barr virus (EBV) infection. The EBV membrane glycoprotein gp42 binds to its cell surface receptor major histocompatibility complex class II (MHC-II) to initiate entry into the cell. Also, gp350/220 binds to its cell surface receptor CD21 for entry. Interaction with CD21 initiates signaling cascades that prime resting B cells for persistent latent infection. Following endocytosis, the virion and packaged tegument proteins are released into the cytoplasm following fusion of the virion membrane with endosomal membrane. In particular, BNRF1 disrupts the Daxx/ATRX repressor complex to facilitate viral gene expression.

as a latent protein in BamHI W promoter (Wp)-restricted BL cell lines and LCLs²¹. These findings implicate BHRF1 and BALF1 proteins as playing an important role in the evasion of apoptosis during latency; however, virally encoded miRNAs also cluster at the *BHRF1* locus. Following induction of viral replication in latency I restricted Akata cells, these miRNAs are detectable at 24 hours post stimulation and have been shown to drive proliferation and aid in the evasion of apoptosis^{22–24}.

Hyper-proliferation

Following the pre-latent phase, the initial Epstein-Barr nuclear antigen (EBNA) latency promoter, Wp, is active promoting expression of *EBNA-LP* and *EBNA2*. Subsequently, these proteins transactivate the viral C promoter, Cp, to initiate expression of the EBNA3s and EBNA1 along with their own transcripts to high levels. This EBNA-only gene expression state is associated with a period of rapid proliferation with the first three or four divisions occurring

once every 8 to 12 hours²⁵. This period lasting approximately the first 2 weeks following resting B-cell infection is termed latency I^{26,27}. At this time, the virus expresses all of the EBNA proteins and minimally expresses latent membrane proteins (LMPs) 1, 2A, and 2B²⁶. LMP1 is expressed as early as 2 days post infection; however, during this period, inhibition of early nuclear factor-kappa B (NFκB) activation does not affect transformation, supporting the distinction of this latency phase from the LCL state, which requires LMP1-mediated NFκB activity for survival²⁶.

As a consequence of this rapid proliferation, EBV-infected B cells are susceptible to growth arrest induced by hyper-proliferation-associated DNA damage response^{26,28}. Cells then transition from a period of rapid proliferation and high Myc activity to the steady-state proliferation (about 24 hours per cycle) observed in LCLs with lower Myc and high NFκB activity^{26,29,30}. The high Myc/low NFκB state that occurs during latency I²⁶

might play a role in immune evasion as elevated Myc and low NFκB as observed in BL have been implicated in downregulation of MHC class I and II (MHC-I and MHC-II) and avoidance of T-cell recognition and killing^{29,30}.

Epstein-Barr virus infection in gastric cancer

Viral entry into epithelial cells is primarily mediated by three CD21-independent mechanisms. First, EBV can enter into epithelial cells by close membrane-to-membrane contact of EBV-infected lymphocytes to uninfected epithelial cells. Second, cell-free virus can enter polarized epithelial cells through their basolateral membranes which is mediated in part by interaction between BMRF2 and beta1 and alpha5beta1 integrins. The third mechanism is by lateral spread through the epithelium from infected to uninfected epithelial cells³¹. EBV-associated gastric carcinomas (EBVaGCs) are epithelial in origin and make up approximately 9% of all gastric carcinomas worldwide³². EBVaGCs characteristically acquire mutations within the cellular *PIK3CA* gene and display extreme cellular DNA hyper-methylation. Specifically, mutations in *PIK3CA* identified in intestinal-type gastric cancers were associated with an increased tumor incidence in the lower third of the stomach compared with those without³³. Also, *PIK3CA* mutations in diffuse-type gastric cancer were associated with an increased tumor incidence in the upper third of the stomach and an increased association with hematogenous metastasis. Tumors identified with *PIK3CA* mutation in the middle third of the stomach had an increased association with EBV infection and increased peritoneal recurrence; however, *PIK3CA* mutations did not demonstrate a significant effect on patient outcomes.

EBVaGCs are also known to have increased expression of JAK2, programmed death ligand 1 (PD-L1), and PD-L2³⁴. PD-L1 is known to interact with programmed death receptor 1 found on the surface of T cells. This interaction causes the inhibition of T-cell proliferation, cytokine secretion, and cytotoxic activity (reviewed in 35). Also, EBVaGCs have been shown to express BNLF2a, which functions in immune evasion by inhibiting the transporter associated with antigen-processing transport of antigenic peptides. Though this transcript is typically associated with lytic replication, in gastric cancers it is expressed latently and has the potential to protect the infected cell from immunosurveillance³⁶. Despite the immunologically evasive nature of EBVaGC, patients with diagnosed EBVaGC had longer survival post diagnosis as opposed to EBV-negative gastric carcinoma³⁷.

Infection of an EBV-negative GC cell line (AGS) with Akata EBV results in robust expression of virally encoded BART miRNAs with minimal protein expression³⁸. Importantly, these infected AGS cells displayed a more transformed phenotype than their uninfected counterparts. The prototypical transforming EBV strain, B95-8, readily infects and immortalizes human B cells. However, this virus is deleted for most of the BART miRNAs, and infection of B cells with viral variants encoding these miRNAs results in minimal BART expression^{39,40}. This tissue-specific BART expression suggests that these miRNAs are likely to play a significant role in the transformed growth properties of EBVaGC.

Recently, it has been shown that CRISPR/Cas9-mediated cleavage for bacterial artificial chromosome (BAC) insertion into EBV episomal DNA in gastric carcinoma (GC) cell lines has facilitated the cloning of these viral genomes with unprecedented efficiency⁴¹. Subsequent infection of epithelial cells with the BAC clone reconstituted viruses induced resistance to oncogene-induced cell death, providing important clues concerning EBV-mediated epithelial carcinogenesis. Establishing this new state-of-the-art technique will enable future investigation into new strain variations and their relationship with EBV-associated disease.

Epstein-Barr virus strain variation

Recent advances in next-generation whole genome sequencing (NGS) have changed the landscape surrounding the analysis of EBV-type differences. Historically, the major distinction in EBV strains has been the delineation of type 1/type 2. Currently, the largest distinguishing factors between EBV type 1 and type 2 rely on differences observed in the *EBNA2* and *EBNA3A*, *EBNA3B*, and *EBNA3C* genes. Indeed, it has been shown that a single amino acid change in the transactivation domain of EBV-2 EBNA2 (S442D) can drastically alter EBV-2 B-cell transformation efficacy similar to that observed with EBV-1 and increase induction of LMP1 expression with a higher affinity for the LMP1 promoter⁴². However, a number of other factors may contribute to the underlying strain variation, including immunological pressures, skewed cell tropism, and geographic isolation⁴³. Indeed, a recently described strain of EBV derived from a nasopharyngeal carcinoma case, M81, displays high epithelial tropism and also contains a polymorphism in the promoter of the lytic transactivator BZLF1 leading to elevated lytic replication⁴⁴.

It has been proposed that the prevalence of MHC haplotypes within specific geographic regions induces immunological pressures that can contribute to strain variation within immunologically dominant epitopes of particularly immunogenic proteins⁴⁵. However, recent sequence analyses demonstrate that the large numbers of non-synonymous mutations observed in the EBNA3 proteins are outside of known cytotoxic T-cell epitopes. More work is needed to identify alternative cytotoxic T lymphocyte (CTL) epitopes within the EBNA3s to explain this variation, or alternatively another selective pressure could be driving this variation perhaps regarding EBNA3 function⁴³. For example, a recent study found that EBNA3B, an immunodominant latency protein, actually serves as a tumor suppressor and can be found deleted in EBV strains associated with diffuse large B-cell lymphomas (DLBCLs)⁴⁶.

Recently, a provocative study implicated EBV-2 as having unique cell tropism skewing toward CD8⁺ T cells⁴⁷. EBV has also been commonly detected in non-B cells in the blood of patients with EBV-positive lymphoproliferative disorder (LPD), including patients with HIV, post-transplant, aplastic anemia, chronic active EBV (CA-EBV), and others^{48,49}. While CA-EBV patients often had EBV⁺ T cells in the blood, other EBV⁺ LPD patients contained EBV in monocytes as well as non-B, non-T, non-monocyte cell types based on surface staining⁴⁹. Although this population is

certainly skewed from the norm with elevated viral loads and altered EBV immune responses, these findings suggest that EBV infection of T cells may be clinically relevant in some instances. Indeed, the detection of EBV in natural killer (NK)/T lymphomas⁵⁰ and a high percentage of T cells in EBV-associated hemophagocytic lymphohistiocytosis (HLH)⁵¹ suggest that lack of control of EBV infection might be associated with a broadening of cellular tropism. Interestingly, cases of CA-EBV are most commonly reported as being of T and NK cell origin in Asia⁵² and almost entirely B-cell origin in the United States⁵³. Information gained through NGS studies coupled with further virus-host interaction work *in vitro* and clinical observation will lead to a greater understanding of how different EBV strains might achieve these drastic differences in cellular tropism and maintenance of latency in various cell types.

Humanized mouse models of Epstein-Barr virus infection

EBV infection had been restricted to *in vitro* systems until the breakthrough of the scid-hu PBL mouse. Scid-hu PBL mice are based on the C.B-17 severe combined immunodeficient (SCID) mouse, which lack both B and T cells⁵⁴. These mice are injected with human peripheral blood mononuclear cells and, after infection with EBV, effectively model the LPD observed in immunocompromised humans (reviewed in [55](#)). However, these mice have several drawbacks, including frequently observed graft-versus-host disease caused by the human T cells attacking mouse tissue, the transient nature of the engrafted human immune system, and a relatively low level of engraftment. Most importantly, these mice are unable to mount adaptive immune responses with their engrafted immune systems.

In order to overcome the obstacles of the scid-hu PBL mouse model, a new suite of humanized mice was generated by transplantation of non-obese diabetic/SCID (NOD/SCID) animals with hematopoietic stem cells. These NOD/SCID mice have a complete null mutation of the common IL-2 cytokine receptor gamma chain—NOD/LtSz-scid/IL-2 receptor gamma null (NSG), NOD/Shi-scid/IL-2 receptor gamma null (NOG)—and, once transplanted, display a humanized immune system that persists for more than 24 weeks post transplant (reviewed in [56](#)). In this model, the CD34⁺ hematopoietic stem cells are able to differentiate into various mature blood cells, including myelomonocytes, dendritic cells, erythrocytes, platelets, and lymphocytes. B cells undergo normal class switching, produce normal immunoglobulins, and even infiltrate into mucosal tissues in these mice. However, it is important to note that circulating IgG is approximately 1,000 times lower than that observed in immunocompetent humans and that infiltration into mucosal tissues has been demonstrated to be severely attenuated. Differentiated T cells display human MHC-I/HLA-restricted cytotoxic functions: a vast improvement over scid-hu PBL mice⁵⁷. The introduction of the human *HLA* A2 allele into NSG mice transplanted with CD34⁺ hematopoietic stem cells (NSG-*HLA*-A2) resulted in mice capable of reproducing adaptive immune responses known to occur after EBV infection of HLA A2-expressing individuals⁵⁸. These NSG-*HLA*-A2 mice have

been used to demonstrate the essential contribution of NK cells in controlling EBV infection with NK depletion resulting in the development of disseminated EBV⁺ lymphomas⁵⁹. Further still, the BLT-NOD mice were developed by transplantation of autologous human hematopoietic fetal liver CD34⁺ cells into NOD/SCID mice previously implanted with human fetal thymic and liver tissues. This resulted in long-term, systemic human T-cell homeostasis capable of mounting anti-EBV MHC-I and MHC-II restricted adaptive immune responses⁶⁰. Given the vast improvements in small animal models of EBV infection, we now have the tools to study post-transplant LPD in the context of a human immune system, adaptive immune responses to EBV infection, and an experimental model to understand the *in vivo* effects of strain variation and other important biological questions.

Humanized mice have been shown to demonstrate the cardinal features of EBV-associated diseases developing B-cell LPD, EBV-associated HLH, and erosive arthritis resembling rheumatoid arthritis (RA). NOG humanized mice injected with 10³ 50% transforming dose (TD50) of EBV develop B-cell LPD. This LPD models the histological and viral gene expression signature observed in immunocompromised patients. Lower dose infection of less than or equal to 10 TD50 in NOG humanized mice resulted in a persistent asymptomatic infection with adaptive CD8⁺ T-cell responses and virus-specific IgM detectable in the serum of infected animals⁶¹. Infection of NOG humanized mice has also been shown to result in the cardinal features of HLH with infected animals developing hemophagocytosis, erythrocytopenia, thrombocytopenia, hypercytokinemia, histiocyte proliferation and infiltration of activated CD8⁺ T cells into the spleen⁶². EBV has been implicated in the pathogenic manifestation of RA. Patients with this disorder demonstrate elevated EBV reactive antibody titers and impaired lymphocyte responses to EBV, and EBV has been identified in the synovial fluid of patients with RA, indirectly implicating EBV in RA pathogenesis^{63–65}. Modeling this pathological phenotype, humanized NOG mice infected with EBV develop an erosive arthritis. However, these findings are purely morphological and require in-depth molecular characterization to further validate this model⁶⁶. A detailed description of recent publications involving the use of humanized mice in EBV research can be found in [Table 1](#).

Concluding remarks

The recent advances described in this review address many of the key questions facing the EBV field today. With the advent of NGS and the development of humanized mice to better model EBV disease *in vivo*, we now have the tools to better understand the effects of strain variation on the development of EBV-associated diseases. Future research will benefit from further refinement of the humanized mouse models to better model the full spectrum of the human immune response to EBV infection with the aim of developing effective EBV-specific prophylactics and therapeutics. Further studies of the early period after B-cell infection and its contribution to tumorigenesis and immune evasion will be important to study in the humanized mouse. Finally,

Table 1. Epstein-Barr virus humanized mouse studies.

Mouse	Epstein-Barr virus strain	Year	Findings	References
NSG+CD34-depleted human cord blood mononuclear cells	M81 BAC and p2089 B95-8 LMP1-KO	2016	Blocking PD-1/CTLA-4 inhibits Epstein-Barr virus (EBV)-induced lymphoma growth.	67
NSG+purified CD34-positive cells from individual fetal liver samples	GFP-EBV B95-8 WT	2016	Leukocytes lacking cognate HLA ligands interfere with KIR ⁺ natural killer (NK) recognition of HLA- tumors but improve NK-mediated control of EBV infection.	68
NSG-A2tg (expressing HLA-A2)+purified CD34-positive cells from two fetal liver samples	M81BAC, M81BACΔC1, M81BACΔC2, M81BACΔC1C2, M81BACΔb2, and M81BACΔAll	2015	BART microRNAs repress tumorigenesis <i>in vivo</i> and likely facilitate long-term persistence in the infected host.	69
Rag2 ^{-/-} γC ^{-/-} double knockout+human hematopoietic stem cells injected into the liver	293EBV ⁺ and 293EBVdelta (BPLF1-KO)	2015	BPLF1 contributes to EBV oncogenicity.	70
NSG+purified human cord blood CD34-positive hematopoietic stem cells injected into the liver	B95-8	2015	EBV-associated Hodgkin's lymphoma develops exclusively in mice with activated T-cell conditions and EBV-associated non-Hodgkin's lymphoma develops in mice with a largely suppressed T-cell condition predominantly characterized with an abundance of immature B cells.	71
NSG-A2tg +purified human cord blood CD34-positive hematopoietic stem cells injected into the liver	B95-8 BAC, EBER1 or EBER2 deletion mutants, and revertant viruses	2015	Wild-type and EBER-deleted mutant viruses demonstrate equal ability to persist <i>in vivo</i> .	72
NSG+purified human fetal liver CD34-positive hematopoietic stem cells injected into the liver	B95-8 GFP ⁺	2015	The human SAP-dependent 2B4 receptor is required for CD8 ⁺ T cell-mediated control of EBV infection.	73
NSG+purified CD34-positive cells from individual fetal liver samples and fetal thymus from the same donor	p2089 B95-8 BAC and p2089 B95-8 BAC LMP1-KO	2015	LMP1 is not essential for EBV-induced lymphomas <i>in vivo</i> , and T cells supply signals that substitute for LMP1 in EBV-positive B-cell lymphomagenesis.	74
NSG-A2tg +purified human cord blood CD34-positive hematopoietic stem cells injected into the liver	Wild-type B95-8 and BZLF1 knockout	2014	T cells specific for the lytic EBV antigen BMLF1 can effectively control lytically replicating EBV ⁺ B cells <i>in vivo</i> .	75
Rag2 ^{-/-} γC ^{-/-} double knockout+human peripheral blood mononuclear cells (PBMCs) or Vγ9Vδ2-T cell-depleted PBMCs	B95-8 and B95.8EBfaV-GFP	2014	Vγ9Vδ2-T cells contribute to EBV immunity.	76
NSG+purified CD34-positive human cord blood mononuclear cells	B95-8	2014	CD4 ⁺ T cells are necessary for the generation/ maintenance of cells with latency I/IIa phenotype in humanized mice and contribute to this process through expression of CD40L.	77

the role of EBV in epithelial malignancies and other diseases outside of the B-cell compartment is ripe for study in this post-genomic era of EBV biology.

Competing interests

The authors declare that they have no competing interests.

Grant information

This work received funding support from the National Cancer Institute (grant R01CA140337) and the National Institute of Dental and Craniofacial Research (grant R01DE025994).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Knipe DM, Howley PM: **Fields virology**. 6th ed. Philadelphia, PA: Wolters Kluwer/ Lippincott Williams & Wilkins Health. 2013; 2.
[Reference Source](#)
2. Epstein MA, Achong BG, Barr YM: **Virus Particles In Cultured Lymphoblasts From Burkitt's Lymphoma**. *Lancet*. 1964; 1(7335): 702–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Henle W, Diehl V, Kohn G, *et al.*: **Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells**. *Science*. 1967; 157(3792): 1064–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Pope JH, Horne MK, Scott W: **Transformation of foetal human leukocytes *in vitro* by filtrates of a human leukaemic cell line containing herpes-like virus**. *Int J Cancer*. 1968; 3(6): 857–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. **F** Khan G, Hashim MJ: **Global burden of deaths from Epstein-Barr virus attributable malignancies 1990–2010**. *Infect Agent Cancer*. 2014; 9(1): 38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
6. Miller N, Hutt-Fletcher LM: **Epstein-Barr virus enters B cells and epithelial cells by different routes**. *J Virol*. 1992; 66(6): 3409–14.
[PubMed Abstract](#) | [Free Full Text](#)
7. Nemerow GR, Cooper NR: **Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process**. *Virology*. 1984; 132(1): 186–98.
[PubMed Abstract](#)
8. Mullen MM, Haan KM, Longnecker R, *et al.*: **Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1**. *Mol Cell*. 2002; 9(2): 375–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. **F** Arredouani MS, Bhasin MK, Sage DR, *et al.*: **Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection**. *J Virol*. 2014; 88(10): 5559–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
10. Tsai K, Thikmyanova N, Wojcechowskyj JA, *et al.*: **EBV tegument protein BHRF1 disrupts DAXX-ATRX to activate viral early gene transcription**. *PLoS Pathog*. 2011; 7(11): e1002376.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Xue Y, Gibbons R, Yan Z, *et al.*: **The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies**. *Proc Natl Acad Sci U S A*. 2003; 100(19): 10635–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Shaw JE, Levinger LF, Carter CW Jr: **Nucleosomal structure of Epstein-Barr virus DNA in transformed cell lines**. *J Virol*. 1979; 29(2): 657–65.
[PubMed Abstract](#) | [Free Full Text](#)
13. **F** Jochum S, Ruiss R, Moosmann A, *et al.*: **RNAs in Epstein-Barr virions control early steps of infection**. *Proc Natl Acad Sci U S A*. 2012; 109(21): E1396–404.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
14. **F** Albanese M, Tagawa T, Bouvet M, *et al.*: **Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8⁺ T cells**. *Proc Natl Acad Sci U S A*. 2016; 113(42): E6467–E6475.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
15. **F** Tagawa T, Albanese M, Bouvet M, *et al.*: **Epstein-Barr viral miRNAs inhibit antiviral CD4⁺ T cell responses targeting IL-12 and peptide processing**. *J Exp Med*. 2016; 213(10): 2065–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. **F** Kalla M, Schmeink A, Bergbauer M, *et al.*: **AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome**. *Proc Natl Acad Sci U S A*. 2010; 107(2): 850–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
17. Wen W, Iwakiri D, Yamamoto K, *et al.*: **Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes**. *J Virol*. 2007; 81(2): 1037–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Halder S, Murakami M, Verma SC, *et al.*: **Early events associated with infection of Epstein-Barr virus infection of primary B-cells**. *PLoS One*. 2009; 4(9): e7214.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Zhang Q, Gutsch D, Kenney S: **Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency**. *Mol Cell Biol*. 1994; 14(3): 1929–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Altmann M, Hammerschmidt W: **Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis**. *PLoS Biol*. 2005; 3(12): e404.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Kelly GL, Long HM, Stylianou J, *et al.*: **An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link**. *PLoS Pathog*. 2009; 5(3): e1000341.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Feederle R, Linnstaedt SD, Bannert H, *et al.*: **A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus**. *PLoS Pathog*. 2011; 7(2): e1001294.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Seto E, Moosmann A, Grömming S, *et al.*: **Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells**. *PLoS Pathog*. 2010; 6(8): e1001063.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Xing L, Kieff E: **Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication**. *J Virol*. 2007; 81(18): 9967–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Nikitin PA, Yan CM, Forte E, *et al.*: **An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells**. *Cell Host Microbe*. 2010; 8(6): 510–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Price AM, Tourigny JP, Forte E, *et al.*: **Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF- κ B activation**. *J Virol*. 2012; 86(20): 11096–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Klein E, Nagy N, Rasul AE: **EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency**. *Oncotarget*. 2013; 2(2): e23035.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Nikitin PA, Price AM, McFadden K, *et al.*: **Mitogen-induced B-cell proliferation activates Chk2-dependent G1/S cell cycle arrest**. *PLoS One*. 2014; 9(1): e87299.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. **F** God JM, Cameron C, Figueroa J, *et al.*: **Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors**. *J Immunol*. 2015; 194(4): 1434–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
30. Staeger MS, Lee SP, Frisan T, *et al.*: **MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells**. *Proc Natl Acad Sci U S A*. 2002; 99(7): 4550–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. **F** Tugizov SM, Berline JW, Palefsky JM: **Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells**. *Nat Med*. 2003; 9(3): 307–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
32. Shibata D, Weiss LM: **Epstein-Barr virus-associated gastric adenocarcinoma**. *Am J Pathol*. 1992; 140(4): 769–74.
[PubMed Abstract](#) | [Free Full Text](#)
33. **F** Fang WT, Huang KH, Lan YT, *et al.*: **Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers**. *Oncotarget*. 2016; 7(5): 6201–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. **F** Cancer Genome Atlas Research Network: **Comprehensive molecular characterization of gastric adenocarcinoma**. *Nature*. 2014; 513(7517): 202–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. Blank C, Mackensen A: **Contribution of the PD-1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion**. *Cancer Immunol Immunother*. 2007; 56(5): 739–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. **F** Strong MJ, Laskow T, Nakhoul H, *et al.*: **Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas**. *J Virol*. 2015; 89(19): 10110–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
37. **F** Camargo MC, Kim W, Chiaravalli AM, *et al.*: **Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis**. *Gut*. 2014; 63(2): 236–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. Marquitz AR, Mathur A, Shair KH, *et al.*: **Infection of Epstein-Barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression**. *Proc Natl Acad Sci U S A*. 2012; 109(24): 9593–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Raab-Traub N, Dambaugh T, Kieff E: **DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative**. *Cell*. 1980; 22(1 Pt 1): 257–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Edwards RH, Marquitz AR, Raab-Traub N: **Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing**. *J Virol*. 2008; 82(8): 9094–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. **F** Kanda T, Furuse Y, Oshitani H, *et al.*: **Highly Efficient CRISPR/Cas9-Mediated Cloning and Functional Characterization of Gastric Cancer-Derived**

- Epstein-Barr Virus Strains. *J Virol*. 2016; 90(9): 4383–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
42. **F** Tzellos S, Correia PB, Karstegl CE, *et al.*: A single amino acid in EBNA-2 determines superior B lymphoblastoid cell line growth maintenance by Epstein-Barr virus type 1 EBNA-2. *J Virol*. 2014; 88(16): 8743–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 43. **F** Palser AL, Grayson NE, White RE, *et al.*: Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. *J Virol*. 2015; 89(10): 5222–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 44. **F** Tsai MH, Raykova A, Klinke O, *et al.*: Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. *Cell Rep*. 2013; 5(2): 458–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 45. Midgley RS, Bell AI, Yao QY, *et al.*: HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences. *J Virol*. 2003; 77(21): 11507–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. White RE, Ramer PC, Naresh KN, *et al.*: EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. *J Clin Invest*. 2012; 122(4): 1487–502.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. **F** Coleman CB, Wohlford EM, Smith NA, *et al.*: Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. *J Virol*. 2015; 89(4): 2301–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 48. Kimura H, Hoshino Y, Kanegane H, *et al.*: Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. *Blood*. 2001; 98(2): 280–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Calattini S, Sereti I, Scheinberg P, *et al.*: Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. *Blood*. 2010; 116(22): 4546–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Kimura H, Ito Y, Kawabe S, *et al.*: EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. *Blood*. 2012; 119(3): 673–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Fox CP, Shannon-Lowe C, Gothard P, *et al.*: Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. *Clin Infect Dis*. 2010; 51(1): 66–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Kimura H, Morishima T, Kanegane H, *et al.*: Prognostic factors for chronic active Epstein-Barr virus infection. *J Infect Dis*. 2003; 187(4): 527–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Cohen JI, Jaffe ES, Dale JK, *et al.*: Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. *Blood*. 2011; 117(22): 5835–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Mosier DE, Gulizia RJ, Baird SM, *et al.*: Transfer of a functional human immune system to mice with severe combined immunodeficiency. *Nature*. 1988; 335(6187): 256–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Fujiwara S, Matsuda G, Imadome K: Humanized mouse models of Epstein-Barr virus infection and associated diseases. *Pathogens*. 2013; 2(1): 153–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Fujiwara S, Imadome K, Takei M: Modeling EBV infection and pathogenesis in new-generation humanized mice. *Exp Mol Med*. 2015; 47(1): e135.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 57. Ishikawa F, Yasukawa M, Lyons B, *et al.*: Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain^{null} mice. *Blood*. 2005; 106(5): 1565–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Shultz LD, Saito Y, Najima Y, *et al.*: Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2 γ chain^{null} humanized mice. *Proc Natl Acad Sci U S A*. 2010; 107(29): 13022–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. **F** Chijioko O, Müller A, Feederle R, *et al.*: Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. *Cell Rep*. 2013; 5(6): 1489–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 60. **F** Melkus MW, Estes JD, Padgett-Thomas A, *et al.*: Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. *Nat Med*. 2006; 12(11): 1316–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 61. Yajima M, Imadome K, Nakagawa A, *et al.*: A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. *J Infect Dis*. 2008; 198(5): 673–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Sato K, Misawa N, Nie C, *et al.*: A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. *Blood*. 2011; 117(21): 5663–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Toussiot E, Roudier J: Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. *Joint Bone Spine*. 2007; 74(5): 418–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. **F** Erre GL, Mameli G, Cossu D, *et al.*: Increased Epstein-Barr Virus DNA Load and Antibodies Against EBNA1 and EA in Sardinian Patients with Rheumatoid Arthritis. *Viral Immunol*. 2015; 28(7): 385–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 65. **F** Mahabadi M, Faghiloo E, Alishiri GH, *et al.*: Detection of Epstein-Barr virus in synovial fluid of rheumatoid arthritis patients. *Electron Physician*. 2016; 8(3): 2181–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 66. Kuwana Y, Takei M, Yajima M, *et al.*: Epstein-Barr virus induces erosive arthritis in humanized mice. *PLoS One*. 2011; 6(10): e26630.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. **F** Ma SD, Xu X, Jones R, *et al.*: PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. *PLoS Pathog*. 2016; 12(5): e1005642.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 68. **F** Landtwing V, Raykova A, Pezzino G, *et al.*: Cognate HLA absence in *trans* diminishes human NK cell education. *J Clin Invest*. 2016; 126(10): 3772–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 69. **F** Lin X, Tsai MH, Shumilov A, *et al.*: The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates Multiple Functions in Primary B Cells. *PLoS Pathog*. 2015; 11(12): e1005344.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 70. **F** Whitehurst CB, Li G, Montgomery SA, *et al.*: Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice. *mBio*. 2015; 6(5): e01574–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 71. **F** Lee EK, Joo EH, Song K, *et al.*: Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice. *Proc Natl Acad Sci U S A*. 2015; 112(42): 13081–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 72. **F** Gregorovic G, Boulden EA, Bosshard R, *et al.*: Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice. *J Virol*. 2015; 89(22): 11711–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 73. **F** Chijioko O, Marcenaro E, Moretta A, *et al.*: Role of the 2B4 Receptor in CD8⁺ T-Cell-Dependent Immune Control of Epstein-Barr Virus Infection in Mice With Reconstituted Human Immune System Components. *J Infect Dis*. 2015; 212(5): 803–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 74. **F** Ma SD, Xu X, Plowshay J, *et al.*: LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis. *J Clin Invest*. 2015; 125(1): 304–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 75. **F** Antsiferova O, Muller A, Ramer PC, *et al.*: Adoptive transfer of EBV specific CD8⁺ T cell clones can transiently control EBV infection in humanized mice. *PLoS Pathog*. 2014; 10(8): e1004333.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 76. **F** Xiang Z, Liu Y, Zheng J, *et al.*: Targeted activation of human V γ 9V δ 2-T cells controls Epstein-Barr virus-induced B cell lymphoproliferative disease. *Cancer Cell*. 2014; 26(4): 565–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 77. **F** Heuts F, Rottenberg ME, Salamon D, *et al.*: T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice. *J Virol*. 2014; 88(6): 3235–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

- 1. Bo Zhao**
Brigham and Women's Hospital, Harvard Medical School, Boston, USA
Competing Interests: No competing interests were disclosed.
- 2. Richard M. Longnecker**
Northwestern University, Chicago, Chicago, IL, USA
Competing Interests: No competing interests were disclosed.
- 3. Alan K Chiang**
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong
Competing Interests: No competing interests were disclosed.
- 4. Christian Münz**
Department of Viral Immunology, Institute of Experimental Immunology, University of Zürich, Zurich, Switzerland
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research